The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases

doi 10.1021/acschembio.9b00289.s001
Full Text
Abstract

Available in full text

Date

Unknown

Authors

Unknown

Publisher

American Chemical Society (ACS)

Related search

Deferasirox, an Oral Iron Chelator, Prevents Hepatocarcinogenesis and Adverse Effects of Sorafenib

Journal of Clinical Biochemistry and Nutrition
MedicineNutritionClinical BiochemistryDietetics
2016English

In Vitro Enzyme Assays for JmjC-Domain-Containing Lysine Histone Demethylases (JmjC-KDMs)

Current Protocols in Pharmacology
MedicinePharmacology
2018English

Histone Deacetylation: IP4 Is an Epigenetic Coregulator

Nature Chemical Biology
Cell BiologyMolecular Biology
2012English

Proteomic Profiling Reveals That Collismycin a Is an Iron Chelator

Scientific Reports
Multidisciplinary
2016English

Histone Demethylases in Cancer

Current Pharmacology Reports
BiochemistryDrug DiscoveryGeneticsPharmacology
2015English

Histone Lysine Demethylases inDrosophila Melanogaster

Fly
Insect Science
2015English

Histone Hypomethylation Is an Indicator of Epigenetic Plasticity in Quiescent Lymphocytes

EMBO Journal
ImmunologyMolecular BiologyBiochemistryMicrobiology NeuroscienceMedicineGenetics
2004English

Targeting Histone Demethylases in Cancer Therapy

Clinical Cancer Research
Cancer ResearchOncology
2009English

PR Domain-Containing Protein 7 (PRDM7) Is a Histone 3 Lysine 4 Trimethyltransferase

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy